1. "2023"
Formats
  1. Journal Article (2318)
  2. Meeting Abstract (1954)
  3. Review (629)
  4. Editorial (353)
  5. Book Section (144)
  6. Research Letter (101)
  7. Guidelines (97)
  8. Correspondence (91)
  9. Miscellaneous (57)
  10. Conference Paper (50)
  11. Book Whole (10)
Groups
  1. Department of Medicine (2451)
  2. Solid Tumor Oncology Division (1380)
  3. Sloan Kettering Institute Postdocs (1151)
  4. Hematologic Malignancies, Division of (1038)
  5. GSK Faculty (1016)
  6. Surgery (930)

More Groups

People
  1. Saad Usmani (123)
  2. Sergio Giralt (104)
  3. Miguel-Angel Perales (101)
  4. Gilles Salles (97)
  5. Gunjan Shah (85)
  6. Michael Scordo (81)

More People

Years
  1. 2023 (5804)
Publications
  1. Journal of Clinical Oncology (553)
  2. Blood (402)
  3. Annals of Oncology (154)
  4. Annals of Surgical Oncology (120)
  5. International Journal of Radiation Oncology, Biology, Physics (116)
  6. Laboratory Investigation (88)

More Publications

Publishers
  1. Elsevier Inc. (762)
  2. American Society of Clinical Oncology (606)
  3. American Society of Hematology (478)
  4. Springer (375)
  5. Oxford University Press (359)
  6. Nature Publishing Group (339)

More Publishers

Results (5804)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Belantamab mafodotin for relapsed or refractory multiple myeloma: A real-world observational study update
    Meeting Abstract

    Hultcrantz, M.; Kleinman, D.; Vij, R.; Escalante, F.; Delforge, M.; Kotowsky, N.; Bitetti, J.; Boytsov, N.; Camadoo-O'Byrne, L.; Happ, L. P.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Early mortality in multiple myeloma- A SEER data analysis
    Meeting Abstract

    Wei, J.; Shastri, A.; Sica, R. A.; Mantzaris, I.; Kornblum, N.; Shah, U.; Janakiram, M.; Gritsman, K.; Verma, A.; Goldfinger, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Adjusted indirect treatment comparison of progression-free survival associated with D-Rd and VRd based on MAIA and SWOG S0777 individual patient-level data
    Meeting Abstract

    Durie, B. G. M.; Kumar, S. K.; Ammann, E. M.; Fu, A. Z.; Kaila, S.; Lam, A.; Usmani, S. Z.; Facon, T.
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Idecabtagene vicleucel (ide-cel) versus standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): A KarMMa-3 analysis in high-risk subgroups
    Meeting Abstract

    Patel, K.; Rodríguez-Otero, P.; Manier, S.; Baz, R.; Raab, M. S.; Cavo, M.; Callander, N.; Costa, L. J.; Moreau, P.; Solomon, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Lin, Y.; Martin, T.; Usmani, S.; Berdeja, J.; Jakubowiak, A.; Agha, M.; Cohen, A.; Deol, A.; Htut, M.; Lesokhin, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients with relapsed/refractory multiple myeloma (RRMM): Extended follow-up and biweekly administration from the MagnetisMM-3 study
    Meeting Abstract

    Mohty, M.; Tomasson, M. H.; Arnulf, B.; Bahlis, N. J.; Prince, H. M.; Niesvizky, R.; Rodríguez-Otero, P.; Martínez-Lopez, J.; Koehne, G.; Jethava, Y.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Real-world patient profile and step-up dosing process of early initiators of teclistamab for multiple myeloma (MM) in a hospital setting in the US: Premier Healthcare Database study
    Meeting Abstract

    Tan, C. R.; Chinaeke, E.; Kim, N.; Hester, L.; Fowler, J.; Gifkins, D.; Lin, D.; Walker, S.; Fu, A. Z.; Wu, B.
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: Pooled analysis from MagnetisMM Studies
    Meeting Abstract

    Nooka, A. K.; Lesokhin, A. M.; Mohty, M.; Niesvizky, R.; Maisel, C.; Arnulf, B.; Larson, S. M.; Varshavsky-Yanovsky, A. N.; Leleu, X.; Karlin, L.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Efficacy outcomes and characteristics of patients with multiple myeloma (mm) who achieved sustained minimal residual disease negativity after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1
    Meeting Abstract

    Munshi, N.; Pavia, B.; Martin, T.; Usmani, S.; Lin, Y.; Schecter, J.; Jackson, C.; Madduri, D.; Zudaire, E.; Yeh, T. M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • A multi-institutional prospective cohort study of minimal residual disease in peripheral T-cell lymphoma: Impact of autologous stem cell transplant (ASCT)
    Meeting Abstract

    Foley, N.; Russler-Germain, D.; Watkins, M.; Jacobsen, E.; Moskowitz, A.; Cashen, A.; Fehniger, T.; Kahl, B.; Bartlett, N.; Ghobadi, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save